This study is looking at how safe a new treatment is for kids with high-risk acute myeloid leukemia (AML), a type of blood cancer. The treatment uses a mix of drugs called ASTX727 (cedazuridine and decitabine) and filgrastim. Cedazuridine helps decitabine work better by stopping it from breaking down too fast in the body. Decitabine helps the body make normal blood cells and kills cancer cells. Filgrastim helps decitabine work even better.
In this study, kids will take these medicines after receiving a special type of blood cell transplant. The main goal is to find the highest safe dose of the medicines and understand any side effects. Kids will take ASTX727 by mouth for five days in a row and filgrastim for six days, repeated every 28 days for up to a year.
- The study lasts up to 1 year with regular check-ups.
- Participants must be 21 or younger and have had a specific type of blood transplant.
- Frequent blood tests and check-ups are required throughout the study.